Abstract
Tumor analysis in mHM and mHMTA. A, Comparison of the average mouse tumor burden on mHM (n = 27 on nine mice) and mHMTA (n = 30 on 10 mice) shows that PDX growth on mHMTA is significantly slowed (P = 0.007, linear mixed-effects model). B, Comparison of tumor volumes also indicates slower PDX growth in mHMTA (P = 0.003, linear mixed-effects model). For A and B, the marginal fit plus the residuals are plotted for each mouse/tumor at each timepoint are shown as circles. C, PFS (defined as a 20% increase in volume from the starting date) analysis of mHM and mHMTA tumors (P = 0.0006, cumulative HR). D, Ki67 IHC staining of mHM and mHMTA tumors showing the depth of thickness of living cells surrounding the necrotic tumor core. Magnification is 5×; scales bar, 100 μm. E, Quantification of the depth of these proliferating cells from the tumor edge (P = 0.048, two-group t test). F, Normalized comparison of mHM and mHMTA tumor volumes reveals a significant reduction in mHMTA (P = 0.019, two-group t test). G, Likewise, a normalized comparison of mHM and mHMTA live tumor volumes indicates a significant reduction in mHMTA (P = 0.034, two-group t test). H, A comparison of human CD45+ cell infiltration in the tumors of mHM and mHMTA (P = 0.743, Wilcoxon rank-sum test). I, A comparison of T-cell infiltration in mHM and mHMTA tumors (P = 0.468, Wilcoxon rank-sum test). J, IHC of CD3/45+ T cells (indicated by arrows) infiltrating the mHM and mHMTA tumors. Magnification is 40×; scale bar, 50 μm. K, Quantification of human CD45+ lymphocytes within the tumor tissue and capsule indicates increased infiltration within mHMTA tumors (P = 0.0207, Wilcoxon rank-sum test). L, Quantification of human CD3+ T cells within the tumor tissue and capsule likewise revealed increased infiltration in mHMTA tumors (P = 0.0107, Wilcoxon rank-sum test). P values: *, ≤0.05; **, ≤0.01; ***, ≤0.001. huCD3, human CD3; huCD45, human CD45.